Application of permeability-limited physiologically-based pharmacokinetic models: Part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3145-3160

  Neuhoff, Sibylle ^a   Yeo, Karen Rowland ^a   Barter, Zoe ^a   Jamei, Masoud ^a   Turner, David B ^a   Rostami Hodjegan, Amin ^a,b  

^a CERTARA UK LIMITED   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

ABCB1; Digoxin; IVIVE; MDR1; P glycoprotein; Pharmacokinetics; Simulation; Transporter

Indexed keywords

ACETYLDIGOXIN; DIGOXIN; MULTIDRUG RESISTANCE PROTEIN;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); METABOLIC CLEARANCE RATE; MULTIPLE DRUG DOSE; PHYSIOLOGICAL PROCESS; PROTEIN EXPRESSION; SIMULATION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABCB1; DIGOXIN; IVIVE; MDR1; P-GLYCOPROTEIN; PHARMACOKINETICS; SIMULATION; TRANSPORTER;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ARRHYTHMIA AGENTS; COMPUTER SIMULATION; DIGOXIN; HUMANS; INTESTINES; LIVER; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PERMEABILITY;

EID: 84881609555     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23594     Document Type: Article

References (84)

1. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 1989. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37(2):159-164.
2. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104(2):147-153.
3. Ochs HR, Greenblatt DJ, Bodem G, Harmatz JS. 1978. Dose-independent pharmacokinetics of digoxin in humans. Am Heart J 96(4):507-511.
4. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A. 1996. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 48(10):1083-1089.
5. Ma JD, Tsunoda SM, Bertino JS Jr., Trivedi M, Beale KK, Nafziger AN. 2010. Evaluation of in vivo P-glycoprotein phenotyping probes: A need for validation. Clin Pharmacokinet 49(4):223-237.
6. Park GD, Spector R, Goldberg MJ, Feldman RD. 1987. Digoxin toxicity in patients with high serum digoxin concentrations. Am J Med Sci 294(6):423-428.
7. Piergies AA, Worwag EM, Atkinson Jr AJ. 1994. A concurrent audit of high digoxin plasma levels. Clin Pharmacol Ther 55(3):353-358.
8. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, Tucker G. 2009. Population-based mechanistic prediction of oral drug absorption. AAPS J 11(2):225-237.
9. Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. 2010. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: A simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr Drug Metab 11(9):716-729.
10. Harwood MD, Neuhoff S, Carlson GL, Warhurst G, Rostami-Hodjegan A. 2012. Absolute abundance and function of intestinal drug transporters: A prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. Biopharm Drug Dispos 34(1):2-28.
11. Zhao P, Rowland M, Huang SM. 2012. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 92(1):17-20.
12. Yu L, Gatlin L, Amidon G. 2000. Predicting oral drug absorption in humans. In Transport processes in pharmaceutical systems; Amidon G, Lee P, Eds. New York: Marcel Dekker, pp 377-409.
13. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. 2009. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5(2):211-223.
14. Tam D, Tirona RG, Pang KS. 2003. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos 31(4):373-383.
15. Cong D, Doherty M, Pang KS. 2000. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. Drug Metab Dispos 28(2):224-235.
16. Ho S, Darwich AS, Jamei M, Rostami-Hodjegan A. In press. Advances in physiologically based modeling coupled with in vitro-in vivo extrapolation of ADMET: Assessing the impact of genetic variability in hepatic transporters. In Encyclopedia of Toxicology; Wexler P, Ed. 3rd ed. Amsterdam: Elsevier. (In press)
17. Rodgers T, Leahy D, Rowland M. 2005. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94(6):1259-1276.
18. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95(6):1238-1257.
19. Rodgers T, Rowland M. 2007. Mechanistic approaches to volume of distribution predictions: Understanding the processes. Pharm Res 24(5):918-933.
20. Andersson KE, Bertler A, Wettrell G. 1975. Post-mortem distribution and tissue concentrations of digoxin in infants and adults. Acta Paediatr Scand 64(3):497-504.
21. Doherty JE, Perkins WH, Flanigan WJ. 1967. The distribution and concentration of tritiated digoxin in human tissues. Ann Intern Med 66(1):116-124.
22. Karjalainen J, Ojala K, Reissell P. 1974. Tissue concentrations of digoxin in an autopsy material. Acta Pharmacol Toxicol (Copenh) 34(5):385-390.
23. Troutman MD, Thakker DR. 2003. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 20(8):1200-1209.
24. Kalvass JC, Pollack GM. 2007. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: Implications for understanding and predicting the effects of efflux inhibition. Pharm Res 24(2):265-276.
25. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, Nagar S, Pang KS, Korzekwa K, Swaan PW, Taub ME, Zhao P, Galetin A.ITC recommendations on transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin Pharmacol Ther (In Press, epub date 2013/04/17).
26. Ohnhaus EE, Dettli L, Spring P. 1972. Protein binding of digoxin in human serum. Eur J Clin Pharmacol 5:34-36.
27. Hinderling PH, Hartmann D. 1991. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit 13(5):381-401.
28. Imawaka H, Ito K, Kitamura Y, Sugiyama K, Sugiyama Y. 2009. Prediction of human bioavailability from human oral administration data and animal pharmacokinetic data without data from intravenous administration of drugs in humans. Pharm Res 26(8):1881-1889.
29. Obach RS, Lombardo F, Waters NJ. 2008. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36(7):1385-1405.
30. Hinderling PH. 1984. Kinetics of partitioning and binding of digoxin and its analogues in the subcompartments of blood. J Pharm Sci 73(8):1042-1053.
31. m-values of cardenolides (author's transl). Arzneimittelforschung 28(12):2179-2182.
32. +-ATPase. Br J Pharmacol 91(1):31-38.
33. Eckermann G, Lahu G, Nassr N, Bethke TD. 2012. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults. J Clin Pharmacol 52:251-257.
34. Ragueneau I, Poirier JM, Radembino N, Sao AB, Funck-Brentano C, Jaillon P. 1999. Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. Br J Clin Pharmacol 48(3):453-456.
35. Tayrouz Y, Ding R, Burhenne J, Riedel KD, Weiss J, Hoppe-Tichy T, Haefeli WE, Mikus G. 2003. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther 73(5):397-405.
36. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. 2000. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68(1):6-12.
37. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE. 2004. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 76(1):73-84.
38. Coltart J, Howard M, Chamberlain D. 1972. Myocardial and skeletal muscle concentrations of digoxin in patients on long-term therapy. Br Med J 2(5809):318-319.
39. Wagner JG, Popat KD, Das SK, Sakmar E, Movahhed H. 1981. Evidence of nonlinearity in digoxin pharmacokinetics. J Pharmacokinet Biopharm 9(2):147-166.
40. Koup JR, Greenblatt DJ, Jusko WJ, Smith TW, Koch-Weser J. 1975. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm 3(3):181-192.
41. Rengelshausen J, Goggelmann C, Burhenne J, Riedel KD, Ludwig J, Weiss J, Mikus G, Walter-Sack I, Haefeli WE. 2003. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 56(1):32-38.
42. Kramer WG, Kolibash AJ, Lewis RP, Bathala MS, Visconti JA, Reuning RH. 1979. Pharmacokinetics of digoxin: Relationship between response intensity and predicted compartmental drug levels in man. J Pharmacokinet Biopharm 7(1):47-61.
43. Sumner DJ, Russell AJ. 1976. Digoxin pharmacokinetics: Multicompartmental analysis and its clinical implications. Br J Clin Pharmacol 3(2):221-229.
44. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-Brentano C. 2001. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 70(4):311-316.
45. Kirch W, Hutt HJ, Dylewicz P, Graf KJ, Ohnhaus EE. 1986. Dose-dependence of the nifedipine-digoxin interaction? Clin Pharmacol Ther 39(1):35-39.
46. Troutman MD, Thakker DR. 2003. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 20(8):1210-1224.
47. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J. 2007. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35(8):1333-1340.
48. Miki Y, Suzuki T, Tazawa C, Blumberg B, Sasano H. 2005. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol 231(1-2):75-85.
49. Nishimura M, Naito S. 2005. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20(6):452-477.
50. von Richter O. 2000. Expression und Funktion arzneimittelmetabolisierender Enzyme und des ABC-Transporters P-Glykoprotein in Dünndarm und Leber des Menschen. Department of chemistry and pharmacy, Tübingen: Eberhard-Karls-Universität Tübingen.
51. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. 2005. Changes in liver volume from birth to adulthood: A meta-analysis. Liver Transpl 11(12):1481-1493.
52. Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, Rostami-Hodjegan A. 2008. Covariation of human microsomal protein per gram of liver with age: Absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab Dispos 36(12):2405-2409.
53. Oliver RE, Jones AF, Rowland M. 1998. What surface of the intestinal epithelium is effectively available to permeating drugs? J Pharm Sci 87(5):634-639.
54. Pade D, Turner D, Jamei M, Antonovic L, Martinez M, Rostami-Hodjegan A. 2011. A performance evaluation of Simcyp Dog-A fully mechanistic physiologically based pharmacokinetic dog model based upon a variety of celecoxib IV and oral formulations. In AAPS Annual Meeting; Washington, D.C.
55. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413-420.
56. Hager WD, Fenster P, Mayersohn M, Perrier D, Graves P, Marcus FI, Goldman S. 1979. Digoxin-quinidine interaction pharmacokinetic evaluation. N Engl J Med 300(22):1238-1241.
57. Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Nielsen-Kudsk F. 1981. Digoxin-verapamil interaction. Clin Pharmacol Ther 30(3):311-316.
58. Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, Gibson C, Roupe K, Evers R, Wagner JA, Stoch A. 2011. Rifampin's acute inhibitory and chronic inductive drug interactions: Experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 89(2):234-242.
59. Jalava KM, Partanen J, Neuvonen PJ. 1997. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 19(6):609-613.
60. Verstuyft C, Strabach S, El-Morabet H, Kerb R, Brinkmann U, Dubert L, Jaillon P, Funck-Brentano C, Trugnan G, Becquemont L. 2003. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 73(1):51-60.
61. Hayward RP, Greenwood H, Hamer J. 1978. Comparison of digoxin and medigoxin in normal subjects. Br J Clin Pharmacol 6(1):81-86.
62. Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN. 1991. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 32(5):569-572.
63. Qiu R, Plowchalk DR, Byon W, Terra SG, Corrigan B, Mordenti J, Fang J, Fullerton T. 2010. Lack of a pharmacokinetic interaction between dimebon (latrepirdine) and digoxin in healthy subjects. Clin Pharmacol Ther 87(S1):S91: PIII-72.
64. Friedrich C, Ring A, Brand T, Sennewald R, Graefe-Mody U, Woerle H-J. 2010. Linagliptin has no pharmacokinetic interactions with digoxin in healthy volunteers. Clin Pharmacol Ther 87(S1):S31: PI-69.
65. Friedrich C, Ring A, Brand T, Sennewald R, Graefe-Mody EU, Woerle HJ. 2011. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet 36(1):17-24.
66. Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP. 2008. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: The role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 48(11):1323-1338.
67. Rodin SM, Johnson BF, Wilson J, Ritchie P, Johnson J. 1988. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther 43(6):668-672.
68. Watanabe C, Kato Y, Ito S, Kubo Y, Sai Y, Tsuji A. 2005. Na+/H +exchanger 3 affects transport property of H+/oligopeptide transporter 1. Drug Metab Pharmacokinet 20(6):443-451.
69. Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A. 2006. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 36(6):473-497.
70. Rodin SM, Johnson BF. 1988. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 15(4):227-244.
71. Weiss M, Li P, Roberts MS. 2010. An improved nonlinear model describing the hepatic pharmacokinetics of digoxin: Evidence for two functionally different uptake systems and saturable binding. Pharm Res 27(9):1999-2007.
72. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, Lee CA. 2009. Drug-drug interactions mediated through P-glycoprotein: Clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85(2):173-181.
73. Sedykh A, Fourches D, Duan J, Hucke O, Garneau M, Zhu H, Bonneau P, Tropsha A. 2013. Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res 30(4):996-1007.
74. Kimoto E, Chupka J, Xiao Y, Bi YA, Duignan DB. 2011. Characterization of digoxin uptake in sandwich-cultured human hepatocytes. Drug Metab Dispos 39(1):47-53.
75. Acharya P, O'Connor MP, Polli JW, Ayrton A, Ellens H, Bentz J. 2008. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells. Drug Metab Dispos 36(2):452-460.
76. De Bruyn T, Ye ZW, Peeters A, Sahi J, Baes M, Augustijns PF, Annaert PP. 2011. Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci 43(4):297-307.
77. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. 2001. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120(2):525-533.
78. Seward DJ, Koh AS, Boyer JL, Ballatori N. 2003. Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem 278(30):27473-27482.
79. Neuhoff S, Ungell AL, Zamora I, Artursson P. 2003. pH-Dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: Implications for drug-drug interactions. Pharm Res 20(8):1141-1148.
80. Olinga P, Merema M, Hof IH, Slooff MJ, Proost JH, Meijer DK, Groothuis GM. 1998. Characterization of the uptake of rocuronium and digoxin in human hepatocytes: Carrier specificity and comparison with in vivo data. J Pharmacol Exp Ther 285(2):506-510.
81. Bi YA, Kazolias D, Duignan DB. 2006. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 34(9):1658-1665.
82. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T. 2004. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A 101(10):3569-3574.
83. Kuo KL, Zhu H, McNamara PJ, Leggas M. 2012. Localization and functional characterization of the rat Oatp4c1 transporter in an in vitro cell system and rat tissues. PLoS One 7(6):e39641.
84. Neuhoff S, Gaohua L, Burt H, Jamei M, Li L, Tucker GT, Rostami-Hodjegan A. in press. Accounting for transporters in renal clearance: Towards a mechanistic kidney model (Mech KiM). In Transporters in drug discovery, development and use; Steffansen B, Sugiyama Y, Ed. New York: Springer. (in press)